AICLRs 31.0+9.1%BERGRs 36.5-14.4%PRLRs 147.7+44.2%AGLRs 16.9+69.1%KAPCORs 51.5+57.5%SITCRs 52.5-4.6%NMLRs 374.1+210.3%NETSOLRs 5,771.3+29.7%BOPRs 138.7-11.7%PSORs 443.1+105.3%NPLRs 18.7+89.3%FMLRs 288.6+94.9%MARIRs 23.5-11.0%THALLRs 140.6+110.3%NRLRs 61.3-22.3%HBLRs 451.9-6.7%SYSRs 1,566.1+36.2%GATMRs 79.9+33.4%GHGLRs 1,075.6+1.5%FCEPLRs 85.0+61.6%PNSCRs 566.1-42.5%AVNRs 463.8+57.3%FFLRs 135.5+33.3%AGTLRs 159.5-34.9%FEROZRs 274.0+45.3%SRVIRs 38.0+63.0%ILPRs 26.7+20.5%KELRs 71.8+64.8%MLCFRs 1.8-5.9%HTLRs 157.8+46.7%PIOCRs 54.6+58.7%IGIHLRs 98.5-4.8%EFERTRs 76.5+20.3%FFCRs 14.2-30.0%GHNIRs 476.1+34.4%PTCRs 14,713.1+1.5%TPLPRs 2,078.1+10.1%UBLRs 355.3-25.8%ISLRs 171.0+2.7%APLRs 38.3+9.0%ABOTRs 4.4-26.4%PKGSRs 61.2+35.3%FABLRs 263.0-1.9%ATLHRs 10.6-5.5%OGDCRs 71.0+43.4%MTLRs 106.9-27.7%NCLRs 5.7+56.9%UNITYRs 758.2+41.8%LUCKRs 67.7+22.9%KTMLRs 158.5+51.2%SNBLRs 172.8+16.1%BWCLRs 196.5+40.1%CHCCRs 25.0-4.0%ASTLRs 9.1+14.5%ITTEFAQRs 12.3-9.9%AGPRs 30.8-42.3%HINOONRs 61.3-35.9%ENGRORs 68.6+46.4%ATRLRs 26.4+81.9%SHELRs 187.1-5.4%JDWSRs 2.1+20.6%EFUGRs 50.9+44.1%KOHCRs 79.1+42.0%BNWMRs 54.3+62.8%GLAXORs 56.9+14.0%CNERGYRs 49.2-1.8%JSBLRs 377.8-24.1%SEARLRs 21.7-21.2%MCBRs 81.8-4.4%BAFLRs 110.1+14.1%TGLRs 236.2-8.1%NCPLRs 27.7+19.9%AIRLINKRs 81.3+23.7%PAELRs 27.5+77.4%PAKTRs 1.7+3.6%INDURs 74.3-34.6%EPCLRs 17.8-50.1%TRGRs 100.9+18.5%SNGPRs 3.6-7.2%MEBLRs 95.1+11.0%PPLRs 12.0+27.2%POLRs 149.8+69.1%BAHLRs 123.3-17.6%GWLCRs 18.0+9.8%ACPLRs 41.8+19.4%FCCLRs 146.4+6.4%HCARRs 752.9-10.6%NBPRs 173.6-16.9%FATIMARs 237.9+68.5%SSGCRs 12.9+40.7%AKBLRs 268.1-10.1%LOTCHEMRs 65.9-7.3%NATFRs 5.0-57.8%MUGHALRs 76.8-47.2%PSMCRs 514.2-32.5%ICIRs 268.1+5.8%HUBCRs 48.3+16.8%NESTLERs 4.6-50.6%ARPLRs 89.9-12.9%DGKCRs 681.9+39.9%PSELRs 113.5-0.4%AICLRs 31.0+9.1%BERGRs 36.5-14.4%PRLRs 147.7+44.2%AGLRs 16.9+69.1%KAPCORs 51.5+57.5%SITCRs 52.5-4.6%NMLRs 374.1+210.3%NETSOLRs 5,771.3+29.7%BOPRs 138.7-11.7%PSORs 443.1+105.3%NPLRs 18.7+89.3%FMLRs 288.6+94.9%MARIRs 23.5-11.0%THALLRs 140.6+110.3%NRLRs 61.3-22.3%HBLRs 451.9-6.7%SYSRs 1,566.1+36.2%GATMRs 79.9+33.4%GHGLRs 1,075.6+1.5%FCEPLRs 85.0+61.6%PNSCRs 566.1-42.5%AVNRs 463.8+57.3%FFLRs 135.5+33.3%AGTLRs 159.5-34.9%FEROZRs 274.0+45.3%SRVIRs 38.0+63.0%ILPRs 26.7+20.5%KELRs 71.8+64.8%MLCFRs 1.8-5.9%HTLRs 157.8+46.7%PIOCRs 54.6+58.7%IGIHLRs 98.5-4.8%EFERTRs 76.5+20.3%FFCRs 14.2-30.0%GHNIRs 476.1+34.4%PTCRs 14,713.1+1.5%TPLPRs 2,078.1+10.1%UBLRs 355.3-25.8%ISLRs 171.0+2.7%APLRs 38.3+9.0%ABOTRs 4.4-26.4%PKGSRs 61.2+35.3%FABLRs 263.0-1.9%ATLHRs 10.6-5.5%OGDCRs 71.0+43.4%MTLRs 106.9-27.7%NCLRs 5.7+56.9%UNITYRs 758.2+41.8%LUCKRs 67.7+22.9%KTMLRs 158.5+51.2%SNBLRs 172.8+16.1%BWCLRs 196.5+40.1%CHCCRs 25.0-4.0%ASTLRs 9.1+14.5%ITTEFAQRs 12.3-9.9%AGPRs 30.8-42.3%HINOONRs 61.3-35.9%ENGRORs 68.6+46.4%ATRLRs 26.4+81.9%SHELRs 187.1-5.4%JDWSRs 2.1+20.6%EFUGRs 50.9+44.1%KOHCRs 79.1+42.0%BNWMRs 54.3+62.8%GLAXORs 56.9+14.0%CNERGYRs 49.2-1.8%JSBLRs 377.8-24.1%SEARLRs 21.7-21.2%MCBRs 81.8-4.4%BAFLRs 110.1+14.1%TGLRs 236.2-8.1%NCPLRs 27.7+19.9%AIRLINKRs 81.3+23.7%PAELRs 27.5+77.4%PAKTRs 1.7+3.6%INDURs 74.3-34.6%EPCLRs 17.8-50.1%TRGRs 100.9+18.5%SNGPRs 3.6-7.2%MEBLRs 95.1+11.0%PPLRs 12.0+27.2%POLRs 149.8+69.1%BAHLRs 123.3-17.6%GWLCRs 18.0+9.8%ACPLRs 41.8+19.4%FCCLRs 146.4+6.4%HCARRs 752.9-10.6%NBPRs 173.6-16.9%FATIMARs 237.9+68.5%SSGCRs 12.9+40.7%AKBLRs 268.1-10.1%LOTCHEMRs 65.9-7.3%NATFRs 5.0-57.8%MUGHALRs 76.8-47.2%PSMCRs 514.2-32.5%ICIRs 268.1+5.8%HUBCRs 48.3+16.8%NESTLERs 4.6-50.6%ARPLRs 89.9-12.9%DGKCRs 681.9+39.9%PSELRs 113.5-0.4%

Compare Watch

AGP

HOLD

AGP Limited

Pharmaceuticals · 0.36% of the KSE-100

Price

Rs 30.77

Market cap

Rs 4.4bn

12-month return

-42.3%

Rank

56 of 101

50composite

Rule-based55

ML ranker41

Conviction59

Why the engine ranks it here

AGP Limited (AGP) screens as fairly valued against the rest of the KSE-100, ranking 56 of 101 on a composite score of 50/100.

AGP Limited sits in the Pharmaceuticals sector and scores best on balance-sheet strength (64/100), weakest on growth (29/100). At PKR 30.77 the shares trade on a P/E of 0.4x, 0.05x book, a 60.0% dividend yield. The Piotroski F-Score is 7 of 9 (strong) and the Altman Z''-Score is 9.54 (financially sound).

What it does well

AGP funds 62.4% of assets with equity.

Balance-sheet strength

AGP turns 3.3% of sales into free cash flow.

Profitability & earnings quality

AGP is valued at 0.4x EV/EBITDA.

Valuation

What holds it back

AGP has fallen -45.9% over the last year excluding the latest month.

Price trend

AGP has compounded revenue at only -0.1% a year over three years.

Growth

AGP returns only 11.2% on invested capital.

Profitability & earnings quality

What would change this view

→ two consecutive quarters of revenue growth above the sector median

Five-pillar breakdown

Each pillar scores the company against sector peers, where 50 is the sector average.

Profitability & earnings quality30% weight60

Valuation25% weight64

Balance-sheet strength20% weight64

Growth15% weight29

Price trend10% weight40

The classic screens

Piotroski tests nine accounting facts about improvement; Altman scores the distance from financial distress.

Piotroski F-Score

7 / 9

strong · 7 of 9 tests passed

Altman Z''-Score

9.54

safe zone · safe above 5.85

Profitable on assets

ROA 8.6%

Cash generative

CFO PKR 14,258m

Returns improving

ROA 8.6% vs 7.5% a year ago

Earnings backed by cash

CFO PKR 14,258m vs profit PKR 12,093m

Deleveraging

debt/assets 0.20 vs 0.20

Liquidity improving

current ratio 2.39 vs 2.30

Margin expanding

gross margin 36.0% vs 34.1%

Assets working harder

asset turnover 1.15x vs 1.20x

No shareholder dilution

144m shares vs 144m

Altman components

Working capital / assets0.279

Retained earnings / assets0.575

Operating profit / assets0.125

Equity / liabilities1.659

Sales / assets1.095

Price history

Weekly closes. Beta 0.58 against the index, annualised volatility 34%, RSI 69.

-29.2% over this window

Reported accounts

The last twelve quarters as filed, in PKR millions. The publication date is what the engine uses to decide when a figure became knowable.

Quarter	Revenue	Gross profit	Operating	Net income	EPS	Filed
2025 Q4	Rs 42.6bn	Rs 12.8bn	Rs 3.8bn	Rs 2.5bn	17.22	2026-04-30
2025 Q3	Rs 42.5bn	Rs 15.3bn	Rs 4.8bn	Rs 3.2bn	22.16	2025-11-14
2025 Q2	Rs 42.9bn	Rs 14.6bn	Rs 4.5bn	Rs 3.0bn	20.84	2025-08-14
2025 Q1	Rs 39.6bn	Rs 15.9bn	Rs 5.2bn	Rs 3.4bn	23.76	2025-05-15
2024 Q4	Rs 36.2bn	Rs 12.4bn	Rs 3.9bn	Rs 2.4bn	16.93	2025-04-30
2024 Q3	Rs 37.4bn	Rs 12.0bn	Rs 3.7bn	Rs 2.2bn	15.24	2024-11-14
2024 Q2	Rs 40.4bn	Rs 14.4bn	Rs 4.5bn	Rs 2.7bn	18.73	2024-08-14
2024 Q1	Rs 38.7bn	Rs 10.6bn	Rs 3.1bn	Rs 1.6bn	11.35	2024-05-15
2023 Q4	Rs 39.8bn	Rs 16.3bn	Rs 5.3bn	Rs 3.2bn	22.08	2024-04-29
2023 Q3	Rs 41.9bn	Rs 15.9bn	Rs 5.1bn	Rs 2.9bn	20.31	2023-11-14
2023 Q2	Rs 45.5bn	Rs 16.3bn	Rs 5.2bn	Rs 3.0bn	20.76	2023-08-14
2023 Q1	Rs 43.0bn	Rs 16.8bn	Rs 5.5bn	Rs 3.2bn	22.34	2023-05-15

Ranked against Pharmaceuticals

Every peer in the same sector, ordered by composite score. These are the companies whose ratios set this one's z-scores.

FEROZFerozsons Laboratories2.1x61

ABOTAbbott Laboratories Pakistan0.4x55

AGPAGP Limited0.4x50

HINOONHighnoon Laboratories0.5x50

GLAXOGlaxoSmithKline Pakistan0.5x48

SEARLThe Searle Company0.5x46

Scored as of 31 December 2025. Generated by an automated screen for research and educational use. Not investment advice, and not a substitute for a SECP-licensed adviser.